文献速递临床试验与 GCP

结合认知矫正与元认知疗法改善伊朗德黑兰成人强迫症患者认知功能并减轻症状严重程度:一项随机对照试验的研究方案

Combining cognitive remediation and metacognitive therapy for improving cognitive functions and reducing symptoms severity of adult patients with obsessive-compulsive disorder in Tehran, Iran: study protocol for a randomized, controlled trial.
PubMed 文献 · Trials · 2025-11-12

该研究方案计划在伊朗德黑兰招募36例成人强迫症患者,按1:1随机分为8周认知矫正团体治疗组(前3次元认知疗法,后5次目标管理训练)或8周等待组,主要结局为耶鲁-布朗强迫量表总分、强迫分数和强迫行为分数的变化,评估认知功能与症状严重程度。

要点

  • 36例成人强迫症患者随机分入8周认知矫正团体治疗组或等待组。
  • 干预前3次为元认知疗法,后5次为目标管理训练,每次2小时。
  • 主要结局为耶鲁-布朗强迫量表总分、强迫分数和强迫行为分数变化。

核心结论

  • 作者假设这种新型认知康复方法可积极影响成人强迫症患者的认知缺陷并减轻症状严重程度。

研究设计与样本

  • 研究为采用优效性框架的随机对照试验方案,计划纳入36例成人强迫症患者。
  • 参与者将从伊朗德黑兰的伊朗精神病医院和脑与认知诊所招募。
  • 参与者按1:1比例随机分配至8周认知矫正团体治疗组或8周等待组,随机化不涉及分层变量。

主要发现

  • 主要结局为耶鲁-布朗强迫量表(Y-BOCS;范围0-40,分数越高症状越严重)总分、强迫分数和强迫行为分数的变化。
  • 次要结局为Conners持续操作任务(CPT)、Stroop色词测验(SCWT)和伦敦塔测验(TOL)的表现分数。
  • 评估在基线、治疗后和3个月随访时进行。

关键数值与推荐

  • 纳入标准包括年龄18-65岁且诊断为强迫症。
  • 排除标准包括共病严重心境或精神病性障碍、活动性医学共病或创伤性脑损伤史。
  • 干预共8次,前3次聚焦元认知疗法,后5次聚焦目标管理训练,每次持续2小时。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with obsessive-compulsive disorder (OCD) experience various cognitive impairments, yet typical treatments do not address these deficits. Goal management training (GMT) is a structured cognitive remediation therapy to enhance executive function. GMT serves as a metacognitive strategy training, improving cognitive control and mindfulness related to executive dysfunction. Given OCD patients' challenges with attention flexibility and control, the efficacy of GMT may be enhanced when combined with a preparatory intervention that builds foundational metacognitive knowledge. Metacognitive therapy (MCT), which targets maladaptive metacognitive beliefs linked to OCD symptoms, has been shown to enhance attentional flexibility and address cognitive deficits in these patients. METHOD: This paper describes the protocol for a randomized controlled trial with a superiority framework that investigates the effectiveness of cognitive rehabilitation as a novel approach combining GMT-derived protocol and MCT for treating OCD. Thirty-six adult patients with a primary diagnosis of OCD will be randomly assigned to either an intervention group, an 8-week cognitive remediation group therapy, or an 8-week waitlist group. Participants will be recruited from Iran Psychiatry Hospital (a specialized psychiatric hospital) and the Brain and Cognition Clinic (an outpatient facility) in Tehran, Iran. Key inclusion criteria include aged 18-65 years and diagnosis of OCD. Exclusion criteria include comorbid severe mood or psychotic disorders, active medical comorbidity, or history of traumatic brain injury. Recruitment will commence on May 15, 2025. Participants will be randomly allocated in a 1:1 ratio to intervention or waitlist control. Randomization will not involve stratification variables. Researchers conducting assessments will be blinded to group allocation, therapists will be blinded to test results, data analysts will be independent of the intervention team, and participants will be instructed not to disclose group material to assessors. Clinical research assistants will recruit participants following diagnostic confirmation by psychiatrists. The initial three of the eight sessions will focus on MCT, and the last five will focus on GMT. Each session will last 2 h. Symptom severity of participants and multiple, separable cognitive aspects sensitive to OCD (attention and response inhibition, processing speed, planning, organization, problem-solving, verbal memory, and pre-morbid intellectual functioning) will be assessed at baseline, after treatment, and at a 3-month follow-up. The primary outcome will be changes in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS; range 0-40, with higher scores indicating more severe symptoms) total, obsessive, and compulsive scores. Secondary outcomes will be performance scores on Conners' continuous performance task (CPT), Stroop Color and Word Test (SCWT), and Tower of London (TOL). CONCLUSION: We hypothesize that this novel cognitive rehabilitation approach can positively impact cognitive deficits and reduce the severity of symptoms in adult patients with OCD. TRIAL REGISTRATION: The trial was registered at the Iranian Registry of Clinical Trials on 19/01/2025 ( https://irct.behdasht.gov.ir/trial/81348 (IRCT IRCT20170123032145N8)).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zargarinejad G, Mokhtari S, Mahdavi S, et al. Combining cognitive remediation and metacognitive therapy for improving cognitive functions and reducing symptoms severity of adult patients with obsessive-compulsive disorder in Tehran, Iran: study protocol for a randomized, controlled trial. Trials. 2025. PMID: 41225598. doi:10.1186/s13063-025-09219-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。